The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

A Lower Mainland woman who lives with relapsing-remitting multiple sclerosis is speaking out, calling out what she believes ...

MS is currently treated with 'disease-modifying' medicines (e.g. interferon beta, glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate). These medicines can ...

A new cellular balance test can detect a hidden inflammation in the brain, helping physicians to spot multiple sclerosis ...

There may be two distinct subtypes of multiple sclerosis, according to a new study led by scientists at University College ...

A new study has discovered a possible biomarker linked to multiple sclerosis disease progression that could help identify ...

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today highlighted its 2025 ...

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple sclerosis.

NICE recommends natalizumab, including a lower-cost biosimilar, as a new MS treatment for adults with highly active relapsing-remitting multiple sclerosis, expanding options for thousands of patients ...